The faulty forecasts of pharma firm investors: Misguided cynics miss the promising prognosis for drugmakers Pfizer and Merck
Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.
btimesonline2d
Pfizer Beats Q4 Earnings Estimates as COVID Sales and Cost Cuts Drive Growth
Pfizer Inc. (PFE) exceeded Wall Street expectations in its fourth-quarter and full-year 2024 earnings report, bolstered by ...
Crain's New York2d
Pfizer gets unexpected boost from Covid vaccine and pill
Pfizer's fourth quarter beat expectations on strong sales of its Covid vaccine and pill, bolstering its sales as it seeks to ...
Pfizer Falls on RFK’s Progress Towards Confirmation Despite Good Earnings. Its CEO is Unbothered.
The CEO said last month that the drugmaker had cut costs, revamped its sales operation, and made other big fixes.
Pfizer tops earnings estimates as Covid product sales beat expectations and cost cuts pay off
The results cap off a critical year for Pfizer, which has been slashing costs as it recovers from the rapid decline of its ...
Activist Starboard Value Pushes Becton Dickinson To Divest Life Sciences Unit
Activist investor Starboard Value is urging Becton Dickinson to sell its life sciences division, citing potential value gains. Analysts estimate a spin-off could boost the company's worth by up to 30% ...
Starboard pushes medical device maker Becton Dickinson to spin off unit
Activist investor Starboard Value has taken a stake in Becton Dickinson and is pushing the $72bn medical technology company to sell its life sciences division, according to people familiar with the ...